Ventyx Biosciences initiated with a Buy at Clear Street

Clear Street initiated coverage of Ventyx Biosciences (VTYX) with a Buy rating and $11 price target. The firm notes the stock has two seminal NLRP3 inhibitors’ catalysts that are poised to drive valuation and partnership upside, the analyst tells investors in a research note. The forthcoming Q4 data for VTX2735 may advance it to pivotal recurrent pericarditis trials, supported by $209.0M cash and runway into the second half of 2026, and simultaneously, VTX3232’s Q4 data in obesity-related cardiometabolic diseases will open Sanofi’s (SNY) right-of-first-negotiation window, echoing its August 2025 Vigil acquisition, the firm added.